BioPharma Terug naar discussie overzicht

Genmab, de Deense parel

1. [verwijderd] 9 februari 2007 10:25

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Zie artikel van Marcel Wijma:
   
   www.iex.nl/columns/columns_artikel.as...
2. [verwijderd] 10 februari 2007 08:46

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   CAPITAL INCREASE IN GENMAB AS A RESULT OF EXECUTION OF PRIVATE PLACEMENT TO GLAXOSMITHKLINE
   
   Copenhagen, Denmark; February 7, 2007 - Genmab A/S (CSE: GEN) hereby announces the direct placement of 4,471,202 ordinary Genmab A/S (the "Company" or "Genmab") shares of DKK 1 nominal value each at a subscription price of DKK 454.65 per share in a private placement (the "Placement") to Glaxo Group Limited "GSK". This Placement which is made in connection with the worldwide agreement to co-develop and commercialize HuMax-CD20 was originally announced on December 19, 2006.
   
   Genmab's current share capital amounts to DKK 39,648,355 and will after completion of the capital increase be DKK 44,119,557.
   
   It is expected that the new shares will be admitted for listing on the Copenhagen Stock Exchange on February 9, 2007 after registration with the Danish Commerce and Companies Agency.
   
   The statutory private placement memorandum prepared in Danish in connection with the Placement has been approved by the Danish Financial Supervisory Authority and published in accordance with applicable rules.
   www.genmab.com/upload/filing_of_prosp...
3. [verwijderd] 13 februari 2007 18:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Preliminary Annual Report
   2006
   (February 13, 2007)
   
   Letter from the Chief Executive
   Officer
   Dear Shareholder,
   2006 has been the most exciting year in Genmab’s
   history. Our key achievements in 2006 included entering
   a global co-development and commercialization
   agreement with GlaxoSmithKline (GSK) for HuMax-
   CD20™ (ofatumumab), initiating three new pivotal
   studies, reporting positive results in the HuMax-CD20
   and HuMax-CD4® (zanolimumab) clinical development
   programs, developing the UniBody™ technology
   and completing a private placement of new shares. As
   a result of this careful execution of our business
   strategy, we saw a dramatic increase in Genmab’s
   stock price and market capitalization in 2006. Our
   stock price increased 181% from DKK 135 (approx.
   USD 24) on December 31, 2005 to DKK 380 (approx.
   USD 67) a year later. Our market capitalization also
   significantly increased by 235% from DKK 4.5 billion
   (approx. USD 795 million) to DKK 15.07 billion
   (approx. USD 2.66 billion) in 2006.
   
   Building for a Commercial Future
   Genmab started three new pivotal Phase III clinical
   studies in 2006: HuMax-CD20 for refractory chronic
   lymphocytic leukemia (CLL) and rituximab refractory
   follicular non-Hodgkin’s lymphoma (NHL) and
   HuMax-EGFr™ (zalutumumab) for refractory head
   and neck cancer. We also initiated front line
   combination studies of HuMax-EGFr for head and
   neck cancer and HuMax-CD20 for CLL. Starting front
   line studies with these potential cancer products is a
   new step for Genmab, one that may eventually open up
   more opportunities for our products in the marketplace.
   These pivotal and front line studies have the potential
   to serve as stepping stones on Genmab’s pathway
   towards a commercial future.
   We have also continued to make progress in our
   ongoing development programs. We reported positive
   results in three HuMax-CD20 studies: Phase I/II
   rheumatoid arthritis (RA); interim Phase II RA; and
   Phase I/II CLL duration of response data. In the
   HuMax-CD4 program with Merck Serono S.A. we
   announced positive early results in both the Phase III
   cutaneous T-cell lymphoma (CTCL) and Phase II noncutaneous
   T-cell lymphoma studies. We received Fast
   Track status from the US FDA for HuMax-EGFr in
   refractory head and neck cancer and presented preclinical
   data showing that HuMax-EGFr appears to be
   more effective against variations of the EGF receptor
   than other EGFr directed treatments. We also
   announced that in pre-clinical studies HuMax-CD38™
   was the first antibody shown to inhibit the enzymatic
   activity of the CD38 molecule.
   Genmab remains committed to maintaining a broad and
   diversified product pipeline. With a product portfolio
   consisting of 38 potential products including 18 preclinical
   programs and an additional 14 targets under
   exploration, we are building for the possibility of
   sustained growth in the future.
   
   UniBody - The Next Step in Antibody Development
   Genmab’s scientific team unveiled the innovative new
   UniBody technology that has the potential to increase
   the market for antibody therapeutics. UniBodies are
   stable, smaller antibody formats which, based on preclinical
   data, are expected to last longer in the human
   body than current small antibody formats, lengthening
   the window of opportunity for a treatment to take
   effect. We believe this technology has the potential to
   expand the market for targeted therapeutics especially
   in disease areas like cancer and inflammation where the
   small size and special binding characteristics of
   UniBodies may make them more effective than
   traditional antibody formats. Genmab is beginning to
   develop antibody products using the UniBody
   technology and may consider out-licensing the
   technology to other companies.
   
   www.genmab.com/upload/ifrs_report_200...
4. [verwijderd] 14 februari 2007 16:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Linkje Conference Call
   www.vcall.com/conferences/event.asp?I...
   
   Slides relevant for the conference call can be found on Genmab’s website www.genmab.com. The conference call will be held in English.
5. jokus 14 februari 2007 19:48

   auteur info

   • jokus

     Lid sinds: 04 jul 2002

     Laatste bezoek: 29 jun 2022

   • Aanbevelingen

     Ontvangen: 18

     Gegeven: 0

   •    Aantal posts: 293

   Wederom aankoopmomenten voor Genmab aan 350dkk !
   
   Long in genmab en Crucell .
   
   Gr Jo.
6. [verwijderd] 16 februari 2007 11:47

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   De daling van de laatste dagen blijkt tgv verkoop van de 2.5 M aandelen door Medarex. Een derde hiervan schijnt (volgens Bloomberg) bij GS te zijn gekomen.
   
   Aangezien de vorige CEO Drakeman weg is, is er verder weinig reden om die aandelen aantehouden. Opvoeren kaspositie voor MEDX is ook aantrekkelijk.
   
   De reden van de Genmab koersdaling is dus plausibel. Bijgevolg vandaag weer + 10 DK..
   
   Wellicht koers nu weer verder Up...
   JMHO
7. [verwijderd] 20 februari 2007 12:37

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   More Biotech Cos Seen Listing On Copenhagen Bourse In 07Last update: 2/19/2007 7:34:53 AMSTOCKHOLM
   
   (Dow Jones)--The success of Danish biotechnology companies is expected to encourage more companies in the sector to list on the Copenhagen Stock Exchange in 2007, market watchers say. Jens Peter Toft, global head of corporate finance at Danske Bank, says he expects that 2007 will see healthy initial public offering activity in Denmark dominated in number of transactions by biotechnology companies. "The window for IPOs is definitely there right now. There is a good balance between what sellers and buyers want respectively," he says. Companies mentioned as potential IPO candidates include 7TM Pharma, Natimmune, Egalet, Gastrotech Pharma, Symphogen, Santaris, M2 Medical and Millimed. Florian Schoenharting, co-founder and partner of venture capital firm Nordic Biotech, says that of these, 7TM Pharma stands out as the flagship company. "It has first-class investors involved, they are in phase II with their drug for obesity, which is a big indication, and they have done some international deals," he said. Schoenharting added that Gastrotech and Egalet are also interesting as both companies have good, late-stage products and Egalet also has the advantage of being supported by top venture capital firm Index Ventures. Egalet has two products in late-stage research for the treatment of high blood pressure and pain management and Gastrotech has two drugs in phase II research for catabolic disorders and irritable bowel syndrome. The positive sentiment for biotechnology investments in Denmark has been triggered by a number of companies entering lucrative contracts with international pharmaceutical firms. In December, Genmab A/S (GEN.KO) signed a potential $2.1 billion partnership deal with GlaxoSmithKline PLC (GSK) for its blood cancer drug HuMax-CD20, and shortly after, peer ALK-Abello A/S (ALK-B.KO) entered a contract with Schering-Plough Corp. (SGP), worth up to $255 million for the allergy vaccine Grazax. After nearly five years of no listing activity at all, the Copenhagen stock exchange in the past year and a half has seen three initial public offerings in the biotechnology sector. TopoTarget A/S (TOPO.KO) entered the exchange in June 2005 by raising DKK225 million, followed by Curalogic and LifeCycle Pharma A/S (LCP.KO) in 2006, raising DKK201.6 million and DKK556.6 million, respectively. In total, the biotechnology companies on the Copenhagen Stock Exchange now have a market capitalization of as much as DKK38.8 billion ($6.8 billion.) -By Malin Rising, Dow Jones Newswires; +45 33 111 524; malin.rising@dowjones.com (END) Dow Jones NewswiresFebruary 19, 2007 07:34 ET (12:34 GMT)
8. [verwijderd] 20 februari 2007 13:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Medarex Announces Sale of Shares in Genmab A/S
   Tuesday February 20, 7:00 am ET
   
   PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that it has sold approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 21, 2007. Medarex expects to receive approximately $150 million (USD) in net proceeds from the sale. The sale of Genmab shares is expected to reduce Medarex's equity ownership in Genmab to approximately 11 percent.
   
   Dirk.
   
   --------------------------------------------------------------------------------
   Source: Medarex, Inc.
9. pim f 21 februari 2007 15:31

   auteur info

   • pim f

     Lid sinds: 29 sep 2004

     Laatste bezoek: 08 mei 2024

   • Aanbevelingen

     Ontvangen: 865

     Gegeven: 773

   •    Aantal posts: 4.094

   deze daling is toch wel vrij pittig (324 DK op dit moment), de daling versnelt. ik houd nu ook de vinger aan de buy-knop
10. Edjes1 23 februari 2007 14:04

    auteur info

    • Edjes1

      Lid sinds: 11 apr 2001

      Laatste bezoek: 17 jul 2022

    • Aanbevelingen

      Ontvangen: 133

      Gegeven: 150

    •    Aantal posts: 981

    En weer dalen.
    Het lijkt erop dat er een kop-schouder patroon ontwikkelt? Dan kunnen we terug naar 250....
11. [verwijderd] 23 februari 2007 15:38

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    I'm in! Let's ride!
12. pim f 26 februari 2007 21:27

    auteur info

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 08 mei 2024

    • Aanbevelingen

      Ontvangen: 865

      Gegeven: 773

    •    Aantal posts: 4.094

    quote:

    Edjes1 schreef:

    En weer dalen.
    Het lijkt erop dat er een kop-schouder patroon ontwikkelt? Dan kunnen we terug naar 250....
    

    Met de daling van vandaag (naar 321) ben ik ook wel overtuigd van een terugkeer richting 250. Ik zit helemaal standby om er vol in te kletsen als die 250 benaderd wordt.
13. [verwijderd] 26 februari 2007 21:46

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    op welke beurs noteert Genmab? Ik vind het enkel terug op frankfurt maar weinig handel. Ik zit bij keytradebank...bedankt!
14. pim f 26 februari 2007 22:06

    auteur info

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 08 mei 2024

    • Aanbevelingen

      Ontvangen: 865

      Gegeven: 773

    •    Aantal posts: 4.094

    kopenhagen, kun je via abnamro in beleggen
15. [verwijderd] 27 februari 2007 08:39

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    goedemorgen, ik ben wel nieuw op dit forum maar al langer fan van genmab. Dit fonds kun je gewoon bij SNS-bank internetbeleggen aanschaffen. Je koopt dan op de beurs van Kopenhagen. groeter peter
16. [verwijderd] 27 februari 2007 09:59

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Stimpy1126 schreef:

    op welke beurs noteert Genmab? Ik vind het enkel terug op frankfurt maar weinig handel. Ik zit bij keytradebank...bedankt!
    

    www.genmab.com/InvestorCentre/StockIn...
17. [verwijderd] 27 februari 2007 14:13

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GENMAB TO PRESENT AT NINTH ANNUAL BEAR STEARNS LONDON HEALTHCARE CONFERENCE
    Copenhagen, Denmark; February 22, 2007 – Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Ninth Annual Bear Stearns London Healthcare Conference on February 27 at 12 Noon local time. The conference is being held at the Four Seasons Hotel, Park Lane in London, United Kingdom. Approximately 150 healthcare investors from Europe and the United States are expected to attend the conference.
    Dr. Drakeman’s presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com.
    www.genmab.com/upload/02_bear_stearns...
    
    cc.talkpoint.com/BEAR002/022707b_cy/l...

    Bijlage:
18. Fransk 17 maart 2007 12:40

    auteur info

    • Fransk

      Lid sinds: 24 okt 2004

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 6

    zijn er nog nieuwtjes betreffende genmab?
    Koers is erg onrustig en wil nog niet echt terug naar 425
19. [verwijderd] 19 maart 2007 09:46

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hierbij het laatste nieuws over Genmab. Genmab is present op de grootste wereld conferency van hun beroepsgroep (200 bedrijven) en zal daar weer nieuwe producten presenteren, wil je dit life volgen, dat kan via hun website: www.genmab.com op 21 maart om 10.15.
    
    Copenhagen, Denmark; March 19, 2007 - Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Lehman Brothers Tenth Annual Global Healthcare Conference in Miami on March 21 at 10:15AM local time. The conference will feature presentations from nearly 200 companies in the biotechnology and pharmaceutical industries.
    
    Dr. Drakeman's presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com.
    
    Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US.
    
    Dit zijn de produkten waar Genmab al het alleenrecht voor heeft, dus dat belooft nog wat:
    
    Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM);
    HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
    HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.
    
    groetjes peter
20. [verwijderd] 25 maart 2007 11:18

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Afgelopen vrijdag toch wat stukjes aangeschaft. De potentie van het aandeel is me te groot om links te laten liggen